CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma

CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma

Abstract Introduction Chimeric antigen receptor T‐cell (CAR‐T) therapy is highly effective in B‐cell blood cancers, but there is limited data on its safety and efficacy in intra‐cardiac lymphoma, due to the potential risks of cardiotoxicity and pseudo‐progression. Discussion We discuss four high‐ris...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel H. Chen, Maeve O'Reilly, Kathleen P. Cheok, Ryan Low, Rajesh Puranik, Samuel Clark, John Malcolm Walker, Charlotte Manisty, Arjun K. Ghosh, Claire Roddie
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:eJHaem
Subjects:
B cell non‐Hodgkin lymphoma
cardio‐oncology
cardiovascular adverse events
cardiovascular diseases
chimeric antigen receptor T‐cell
Online Access:https://doi.org/10.1002/jha2.1020
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jha2.1020

Similar Items